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Summary
 
The T cell receptor (TCR) is a versatile receptor able to generate different signals that result in
distinct T cell responses. The pattern of early signals is determined by the TCR binding kinet-
ics that control the ability of the ligand to coengage TCR and coreceptor. Coengagement of
TCR and CD4 results in an agonist signaling pattern with complete tyrosine phosphorylation
of TCR subunits, and recruitment and activation of ZAP-70. In contrast, TCR engagement
without CD4 coengagement causes a partial agonist type of signaling, characterized by distinct
phosphorylation of TCR subunits and recruitment but no activation of ZAP-70. The pathways
triggered by partial agonist signaling are unknown. Here, we show that agonists cause associa-
tion of active lck and active ZAP-70 with p120-GTPase–activating protein (p120-GAP). These
associations follow engagement of CD4 or CD3, respectively. In contrast, partial agonists do
not activate lck or ZAP-70, but induce association of p120-GAP with inactive ZAP-70. De-
spite these differences, both agonist and partial agonist signals activate the mitogen-activated
protein kinase (MAPK) pathway. However, MAPK activation by partial agonists is transient,
supporting a kinetic, CD4-dependent model for the mechanism of action of variant TCR
ligands. Transient MAPK activation may explain some of the responses to TCR partial agonists
and antagonists.
Key words: T cell receptor • partial agonist • signal transduction • mitogen-activated protein 
kinases • p120-GAP
 
T
 
he current paradigm of T cell activation proposes that
signal transduction from the TCR is initiated after
ligand binding by 
 
src
 
-kinase–dependent phosphorylation of
immune receptor, tyrosine- based activation motifs (ITAMs)
 
1
 
in the cytoplasmic domains of the CD3/TCR 
 
z
 
 chains (for
review see reference 1). Phosphorylation of the ITAMs
leads to recruitment and activation of 
 
z
 
-associated protein
(ZAP)-70 through its SH2 domain, and subsequent recruit-
ment and activation of other proteins such as p36 (linker
for activation of T cells) (LAT), vav, and SLP-76, through
SH2–SH3 domain interactions. This leads to the formation
of multimolecular complexes that activate several signaling
cascades such as the phospholipase C-
 
g
 
1 (PLC-
 
g
 
1)–depen-
dent cascade (2), and the ones emanating from activation of
p21
 
ras
 
 such as the mitogen-activated protein kinase
(MAPK) pathway and the phosphatidyl-inositol 3-kinase
(PI-3K) pathway (3–6). These signaling cascades ultimately
converge on the nucleus resulting in the changes of gene
expression that characterize T cell activation.
Implicit in this paradigm is the assumption that similar
levels of TCR occupancy by different ligands will lead to
identical signal transduction events. However, recent evi-
dence indicates that the TCR is not an off/on signal trans-
duction complex, but rather is able to transduce different
patterns of signals that can cause dramatic effects on T cell
function (7, 8). These distinct patterns of early TCR-medi-
ated signaling are induced by variant TCR ligands that
have conservative substitutions in the TCR contact points
of the peptide or the MHC molecule (9, 10). As a result,
they act as partial agonist or antagonist ligands of the TCR
depending on whether they cause partial activation of the
T cell or they inhibit agonist-induced activation (for re-
view see references 11, 12). The differential T cell activa-
tion induced by these variant TCR ligands correlates with
a distinct pattern of early TCR-mediated signaling that is
characterized by predominant appearance of the p21 form
of phospho-
 
z
 
 with little phosphorylation of CD3-
 
e
 
, and
 
1
 
Abbreviations used in this paper:
 
 ERK, extracellular regulated kinase;
MAPK, mitogen-activated protein kinase; p120-GAP, p120-GTPase–
activating protein; PCC(81-104), pigeon cytochrome c fragment 81–104;
ZAP, 
 
z
 
-associated protein.
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with recruitment of ZAP-70 to the TCR-activating com-
plex but no phosphorylation nor activation of this protein
tyrosine kinase (13, 14). This distinct pattern of TCR-
mediated signal results in an array of intracellular changes
that include increase in cell size (10), induction of acidifica-
tion of the extracellular environment (15, 16), transient or
partial calcium signals (17, 18), modulation of TCR expres-
sion (19), and upregulation of some cell surface molecules
such as IL-2 receptor and leukocyte function–associated
antigen 1 (7, 8, 12, 20). These cellular changes translate
functionally into inhibition of agonist-induced cell prolifer-
ation and/or cytokine production, split cytokine produc-
tion profiles, and/or induction of T cell anergy. Together,
this evidence strongly suggests that the distinct pattern of
TCR-mediated signaling induced by partial agonist ligands
can activate, at least, some signaling pathways emanating
from the TCR.
It is not known how the partial agonist type of early
TCR-mediated signaling is transmitted to downstream
pathways. Two general possibilities can be considered. One
is that this differential signaling may transduce distinct or
diminished signals along each one of the pathways emanat-
ing from the TCR, resulting in less signal being delivered
to the nucleus. Alternatively, the early TCR-mediated sig-
naling in partial agonist mode could translate into dissoci-
ated delivery of signals, such as only some of the pathways
emanating from the TCR are activated whereas others are
not. Here, we explore this issue in relation to one of the
pathways emanating from the TCR. Some of the func-
tional responses induced by TCR partial agonist ligands,
such as TCR downmodulation, can be attributed to serine
phosphorylation (21–23). Therefore, we examined the ef-
fects of TCR partial agonists on the Ras-MAPK pathway
of signal transduction, because it primarily involves serine/
threonine kinases and regulates cell proliferation and differ-
entiation (24). Here, we show that signaling from the TCR
in a partial agonist mode causes recruitment of p120-GTP-
ase–activating protein (p120-GAP), a potential Ras effector
molecule, to the receptor, and is capable of activating the
extracellular regulated kinase (ERK)-1 and ERK-2 MAPKs.
However, it does so in a more transient fashion than full
agonist ligands of the TCR do. Our results provide the first
experimental evidence for activation of the MAPK after
partial agonist signaling from the TCR. Activation of the
Ras-MAPK pathway may explain some of the effects seen
after TCR engagement with these variant ligands, such as
downmodulation of TCR or split cytokine production
without proliferation.
 
Materials and Methods
 
Cells.
 
3C6 is a Th1, CD4
 
1
 
 murine T cell clone specific for
pigeon cytochrome c fragment 81–104 [PCC(81-104)] bound to
the I-E
 
k
 
 class II MHC molecule (25). This clone was maintained
by cycles of antigen stimulation with irradiated spleen cells, IL-2–
induced cell expansion, and rest, as previously described (14).
3C6 T cells were used at least 10–14 d after last seeing antigen. L
cells (P13.9), which had been transfected with cDNA constructs
encoding E
 
a
 
 and E
 
b
 
 chains of I-E
 
k
 
, as well as the costimulatory
molecules CD54 (ICAM-1) and CD80 (B7-1), were used as APCs
(14, 26, 27).
 
Reagents.
 
The following peptide was used for these experi-
ments: PCC(81-104) (IFAGIKKKAERADLIAYLKQATAK). This
peptide was commercially provided by Procyon Biopharma Inc.
(London, Ontario, Canada) and purified to 
 
.
 
85% by HPLC be-
fore use. Pervanadate was prepared by dissolving 100 
 
m
 
l of 0.1 M
sodium orthovanadate (Sigma Chemical Co., St. Louis, MO) into
900 
 
m
 
l of double distilled water and 3.3 
 
m
 
l of 30% hydrogen per-
oxide, and kept at room temperature for 15 min before use.
 
Monoclonal Antibodies.
 
4G10 (provided by Dr. B. Druker,
Oregon Health Sciences University, Portland, OR) is a mouse
IgG2b monoclonal antibody against phosphotyrosine, B4F8 is a
mouse IgG2a monoclonal antibody against p120-GTPase activat-
ing protein (p120-GAP; Santa Cruz Biotechnology, Santa Cruz,
CA), rabbit immune sera against lck and ZAP-70 were provided
by L.E. Samelson (CBMB, NICHD, National Institutes of Health,
Bethesda, MD), and H57-597 is a hamster IgG against a common
epitope of the TCR 
 
b
 
 chain. Anti–ACTIVE MAPK (Promega,
Madison, WI) is a rabbit antiserum against dual phosphorylated
MAPK-derived peptide and recognizes MAPK2 enzyme bands at
42/44 kD after cell activation.
The anti-CD3-fos, anti-CD4-jun, and the bivalent anti-CD3-
CD4 fos–jun antibody reagents were prepared by J. Tso (Protein
Design Labs, Palo Alto, CA) and have been previously described
(28–33). These chimeric antibodies combine a Fab fragment
against CD3 or against CD4 linked to fos or jun, respectively. fos
and jun, separately, will form homodimers and will lead to biva-
lent engagement of CD3 in the case of stimulation with anti-
CD3-fos, or to bivalent engagement of CD4 for T cells incubated
with anti-CD4-jun. However, when anti-CD3-fos and anti-
CD4-jun chimeric antibodies are mixed, the equilibrium reaction
is skewed towards fos–jun heterodimerization, and this will result
in CD3-CD4 coengagement (34).
 
T Cell Stimulation.
 
Ag stimulation of T cells was done as pre-
viously described (14, 33). In brief, P13.9 cells (10
 
6
 
 cells/group)
were plated in 24-well plates with or without PCC(81-104), and
incubated at 37
 
8
 
C, overnight. The next day, T cells (10
 
7
 
 cells/
group) were added. Plates were then spun down (1,000 rpm for
30 s) and incubated at 37
 
8
 
C for 10 min. T cell stimulation with
heterofunctional antibodies was performed in a final volume of
100 
 
m
 
l (10
 
7
 
 cells/group) in Eppendorf tubes with the indicated
heterofunctional antibodies (10 
 
m
 
g/ml) or different amounts of
pervanadate for 10 min at 37
 
8
 
C. After stimulation, T cells were
harvested in cold PBS containing sodium orthovanadate (400
 
m
 
M) and EDTA (400 
 
m
 
M), and lysed in 1
 
3 
 
lysis buffer (1% Tri-
ton X-100, 150 mM NaCl, 10 mM Tris, pH 7.6, 5 mM EDTA,
1 mM sodium orthovanadate, 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml
aprotinin, and 25 
 
m
 
M 
 
p
 
-nitrophenyl-
 
p
 
9
 
-guanidino-benzoate).
 
Tyrosine Phosphorylation Analysis.
 
Detection of tyrosine phos-
phorylation of proteins in ZAP-70 or p120-GAP immunoprecip-
itates was performed as described (14). 4G10 monoclonal anti-
body was used for immunoblotting. Rabbit antiserum to ZAP-70
was used to immunoprecipitate ZAP-70 and associated proteins,
and mouse monoclonal antibody against p120-GAP was used for
immunoprecipitation of p120-GAP. Immunoprecipitations were
performed from 10
 
7
 
 cells/group (14). Signal detection was per-
formed by chemiluminescence (Boehringer Mannheim, Laval,
Quebec, Canada) and intensity was quantitated using an imaging
densitometer (model GS 700; BioRad Labs., Hercules, CA) and
the Molecular Analyst
 
Ò
 
 software (version 1.0, BioRad Labs.).
Detection of activated ERK-1 and ERK-2 was performed by 
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Western blotting of cell lysates with the anti–ACTIVE MAPK
(Promega) rabbit antiserum. In brief, 10
 
7
 
 cells/sample was stimu-
lated with the appropriate antibodies at different concentrations
or for different times at 37
 
8
 
C. Next, cells were washed once with
PBS containing sodium orthovanadate, and subsequently lysed in
1
 
3
 
 lysis buffer (500 
 
m
 
l) on ice for 30 min. Lysates cleared of nu-
clear debris by centrifugation at 14,000 rpm at 4
 
8
 
C for 10 min,
and 300 
 
m
 
l of supernatant was mixed with 4
 
3
 
 sample buffer. 30 
 
m
 
l
of this solution (4.5 
 
3 
 
10
 
5
 
cell equivalents/group) were run in
12% SDS-PAGE, transferred to polyvinylidene difluoride mem-
branes, and blotted with anti–ACTIVE MAPK antiserum (Promega)
using chemiluminescence (Boehringer Mannheim).
 
In Vitro Immune Complex Kinase Assays.
 
T cells (10
 
7
 
/sample)
were stimulated with either the anti-CD3-CD4 fos–jun antibod-
ies, the anti-CD3 fos antibodies, or the anti-CD4 jun antibodies
for 10–12 min at 37
 
8
 
C, mixing gently on a thermomixer. Cells
were lysed with 1
 
3
 
 lysis buffer for 30 min on ice. In vitro im-
mune complex kinase assays of lck, ZAP-70, and p120-GAP im-
munoprecipitates were performed as previously described (14).
MAPK activity assay was performed according to manufacturer
specifications (New England Biolabs, Boston, MA). In brief, col-
lected cell lysates were immunoprecipitated with a phospho-specific
p42/p44 MAPK monoclonal antibody on protein A–Sepharose
beads with gentle rocking, overnight at 4
 
8
 
C. The next day, the
bead pellets were washed twice with 1
 
3 
 
lysis buffer and twice
with 1
 
3
 
 kinase buffer (25 mM Tris, pH 7.5, 5 mM 
 
b
 
-glycerol-
phosphate, 2 mM DTT, 0.1 mM sodium orthovanadate, and 10
mM magnesium chloride) and then incubated with the kinase re-
action mix (1
 
3
 
 kinase buffer containing 200 
 
m
 
M ATP) contain-
ing 2 
 
m
 
g of Elk-1 fusion protein for 30 min at 30
 
8
 
C. The reaction
was terminated with 4
 
3
 
 sample buffer and the samples were re-
solved on a 12% SDS-PAGE gel. The separated proteins were
transferred onto PVDF membrane and the membrane was blocked
for 1 h at room temperature. After blocking, the membrane was
incubated in primary antibody solution (a monoclonal antibody
against serine phosphorylated Elk-1) at 4
 
8
 
C overnight. The next
morning, the membrane was washed three times in TBST and
then incubated with a horseradish peroxidase–conjugated second-
ary antibody for 1 h at room temperature. The membrane was
again washed three times with TBST and then incubated for 1 min
with chemiluminescence reagent before film exposure for 5–10 s.
 
Flow Cytometric Analysis of TCR Downmodulation.
 
3C6 T cells
were incubated with different concentrations of heterofunctional
antibodies for 1–3 h at 37
 
8
 
C. Subsequently, T cells were har-
vested and stained with FITC-labeled monoclonal antibody against
mouse TCR-
 
a/b
 
 (H57) or isotype-matched control antibody.
Percentage of downmodulated receptors can be calculated as the
ratio of mean fluorescence value of experimental samples over the
mean fluorescence value of untreated control for the same time
period (35).
 
Results
 
Agonist and Partial Agonist Signaling Patterns from the TCR
Induced by CD3–CD4 Coengagement or by Bivalent CD3 En-
gagement, Respectively.
 
As we have previously reported
(33, 34), coengagement of CD3 and CD4 induces an ago-
nist pattern of early signaling from the TCR. This pattern
is characterized by the presence of two forms of phosphor-
ylated TCR-
 
z
 
 (p21 and p23), phosphorylation of CD3-
 
e
 
,
and recruitment and phosphorylation of ZAP-70 in phos-
photyrosine blots of ZAP-70 immunoprecipitates (Fig. 1).
In contrast, phosphotyrosine blots of ZAP-70 immunopre-
cipitates from T cells stimulated by bivalent engagement of
CD3 show a partial agonist pattern of tyrosine phosphory-
lation. This is identified by predominant appearance of the
p21 form of phospho-
 
z
 
, with little or no phospho-
 
e
 
, and
recruitment but no phosphorylation of ZAP-70 tyrosine
kinase. In previous studies (14, 33), we have shown that the
two patterns of early TCR-mediated signaling are not the
result of quantitative differences in TCR engagement be-
cause they do not overlap after titration of antigenic pep-
tide or stimulating antibody. Bivalent engagement of CD4
alone did not induce significant tyrosine phosphorylation of
TCR subunits in ZAP-70 immunoprecipitates.
Further qualitative differences between the agonist pat-
tern and the partial agonist pattern of early TCR-mediated
signaling were seen when the kinase activity associated
with the TCR complex under conditions of bivalent CD3
engagement or after CD3 and CD4 coengagement were
examined. As genetic and biochemical approaches have
previously demonstrated (36, 37), TCR-mediated signaling
involves recruitment and activation of lck and ZAP-70 ty-
rosine kinases. Consistent with this, we found increased ki-
nase activity associated with lck in T cells activated in an
agonist pattern after CD3 and CD4 coengagement (Fig. 2).
In these conditions, immune complex kinase assays after lck
immunoprecipitation showed increased autophosphoryla-
tion of lck and phosphorylation of a 70-kD band as well as
two bands of 23 and 32 kD, bands compatible with ZAP-
70, TCR-
 
z
 
, and CD3-
 
e
 
, respectively (Fig. 2). ZAP-70
immunoprecipitates showed significant autophosphoryla-
tion of ZAP-70 (Fig. 2). In contrast, no significant increase
of lck phosphorylation or kinase activity was detected in lck
immunoprecipitates or ZAP-70 immunoprecipitates from
cell lysates of T cells activated in a partial agonist mode af-
ter bivalent CD3 engagement alone (Fig. 2). From these
experiments, we concluded that bivalent engagement of
CD3 and coengagement of CD3–CD4 fully reproduce the
distinct patterns of early TCR signaling seen after engage-
ment of TCR with ligands with partial agonist or agonist
properties, respectively (13, 14).
Figure 1. Induction of full ag-
onist or partial agonist patterns of
early TCR-mediated signaling
by coengagement of CD3 and
CD4 or bivalent engagement of
CD3, respectively. 3C6 T cells
(107 cells/lane) were stimulated
with anti-CD3 fos antibodies,
anti-CD4 jun antibodies, or anti-
CD3-fos–anti-CD4-jun anti-
bodies (10 mg/ml) for 10 min.
Cells were lysed and the lysates
underwent immunoprecipitation
with an antiserum against ZAP-
70. Immunoprecipitates were
immunoblotted for phosphoty-
rosine. As positive control, T
cells were stimulated with per-
vanadate, a phosphatase inhibitor. 
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Despite these differences in early TCR-mediated signal-
ing, we found that both agonist ligand and partial agonist
ligand–induced similar loss of surface TCR expression as
measured by flow cytometric analysis using a monoclonal
antibody against mouse TCR (H57-597; Fig. 3). This find-
ing implies that some signals from the TCR are equally
induced by both types of ligands since TCR downmodula-
tion is a reflection of T cell activation (19, 38) and protein
kinase C–dependent serine phosphorylation of CD3 chains
(23, 39–43).
 
Differential Effects of CD3 or CD3–CD4 Engagement on
Recruitment and Phosphorylation of p120-GAP.
 
To explore
the downstream effects of these two qualitatively distinct
patterns of early signaling, we initially looked at recruit-
ment and activation of different molecules involved in the
Ras-MAPK pathway of signal transduction. Among the
many Ras effector molecules, we concentrated on p120-
GAP for three reasons. First, Ag-induced T cell activation
induces tyrosine phosphorylation of p120-GAP (44). Sec-
ond, p120-GAP regulates Ras function by promoting GTPase
activity (45–47). And third, p120-GAP may be itself a Ras
effector molecule (48). We performed p120-GAP immu-
noprecipitates and examined phosphorylation and associa-
tion of p120-GAP after agonist and partial agonist condi-
tions of stimulation. T cell activation in an agonist mode
(either by peptide–MHC molecule complexes on the sur-
face of an APC or by heterofunctional antibodies against
CD3 and CD4) induced a rapid, dose-dependent increase
in phosphotyrosine content of p120-GAP (Fig. 4). In con-
trast, partial agonist signaling from the TCR did not induce
tyrosine phosphorylation of p120-GAP. In addition, biva-
lent CD4 engagement alone did not induce tyrosine phos-
phorylation of p120-GAP either. Despite the differences in
p120-GAP tyrosine phosphorylation, p120-GAP immuno-
precipitation showed a tyrosine-phosphorylated 70-kD band
that was immunoreactive with an antiserum against ZAP-70
in T cells stimulated in full agonist mode (Fig. 5, 
 
a
 
 and 
 
b
 
).
Surprisingly, this 70-kD protein was also associated to
p120-GAP in T cells stimulated in partial agonist mode
(Fig. 5 
 
b
 
), although it was not phosphorylated (Fig. 5 
 
a
 
), in-
dicating that either pattern of early TCR-mediated signal-
ing can induce p120-GAP recruitment to ZAP-70, but
only agonists can induce its phosphorylation.
To further support that this 70-kD band was ZAP-70,
the protein was depleted from the lysate by sequential
rounds of immunoprecipitation with an antiserum against
ZAP-70 (Fig. 6). Interestingly, the data suggest that the
proportion of ZAP-70 that is associated with p120-GAP is
relatively low compared with the total amount of ZAP-70
in the cells. Reblotting of the same membrane with an an-
tiphosphotyrosine antibody showed a similar result for
phospho–ZAP-70. In addition, in vitro immune complex
kinase assays on p120-GAP immunoprecipitates showed
phosphorylated lck and ZAP-70 bands as well as phosphor-
ylation of the cdb3 exogenous substrate for ZAP-70 after
Figure 2. In vitro immune complex kinase assays of lck or ZAP-70 im-
munoprecipitates from T cells stimulated on a full agonist pattern or a
partial agonist pattern of early TCR-mediated signaling. 3C6 T cells (107
cells/lane) were stimulated with the appropriate chimeric antibodies for
10 min. Cells were harvested and lysed, and the lysates subjected to im-
munoprecipitation of lck or ZAP-70. The immunoprecipitates were next
used for in vitro kinase assay after addition of exogenous 32P. Kinase reac-
tions were run in SDS-PAGE and the gels exposed in a phosphorimager.
Identity of the bands and equal loading were confirmed by parallel immu-
noblotting of these immunoprecipitates.
Figure 3. T cell receptor
downmodulation induced by
bivalent engagement of CD3 or
by coengagement of CD3 and
CD4. T cells were incubated
with increasing concentrations of
anti-CD3-fos–anti-CD4-jun an-
tibodies or anti-CD3-fos anti-
bodies for 3 h. T cells were then
harvested and stained with an
FITC-labeled monoclonal anti-
body against TCR-b constant
region (H57-597) and examined
by flow cytometry. Results are presented as a percentage of the mean flu-
orescence value of TCR expression for a given experimental group in re-
lation to a time-matched, nonstimulated control group.
Figure 4. Induction of tyrosine phosphorylation of p120-GAP upon
TCR engagement with agonist ligands. 3C6 T cells (107 cells/lane) were
stimulated with antigenic peptide (1 or 10 mM) and APCs, or with chi-
meric anti-CD3-fos–anti-CD4-jun, anti-CD3-fos, or anti-CD4-jun anti-
bodies at 10 mg/ml for 10 min. T cells were then harvested and lysed in
Triton-X 1%. Cell lysates underwent immunoprecipitation with an anti-
body against p120-GAP and subsequently immunoblotted for phosphoty-
rosine. Equal p120-GAP immunoprecipitation in the different groups was
confirmed by immunoblotting of the same membrane with an antibody
against p120-GAP. 
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CD3–CD4 coengagement (Fig. 7). In contrast, and consis-
tent with our previous findings on kinase assays of ZAP and
lck immunoprecipitates from partial agonist-stimulated T
cells, no kinase activity was detected in p120-GAP immu-
noprecipitates from these cells. The association between
ZAP-70 and p120-GAP is unlikely due to coassociation of
these molecules through TCR subunits because these pro-
teins were not detected in p120-GAP immunoprecipitates.
In these kinase assays, p120-GAP was tyrosine phosphory-
lated only in the immunoprecipitates from T cells stimu-
lated by agonist ligands.
Previous reports have demonstrated that p120-GAP can
associate with lck and is a substrate of this 
 
src
 
-kinase (49,
50). Given that lck is noncovalently associated with CD4
(51), the lack of coengagement of CD3 and CD4 might
translate into lack of association between p120-GAP and lck
and could explain the lack of tyrosine phosphorylation of
p120-GAP. To test this hypothesis, we examined whether
the two patterns of early TCR-mediated signaling differed
in the ability of p120-GAP to associate with lck. As shown
in Fig. 5 
 
c
 
, there is no association between p120-GAP and
lck under basal conditions. However, after TCR-mediated
signaling by the agonist, there was significant association of
these two molecules. Both the p56 and the activation-
dependent p59 form of lck were present in p120-GAP im-
munoprecipitates of T cells stimulated by coengagement of
CD3 and CD4 confirming that T cell activation had oc-
curred. Partial agonist type of TCR-mediated signaling re-
sulted in no association of these two molecules. Of note
was the observation that bivalent engagement of CD4
alone did induce the association of p120-GAP with lck as
well as tyrosine phosphorylation of p120-GAP in immune
complex kinase assays (Fig. 7); however, under these con-
ditions only the resting p56 form of lck was detected.
Thus, our results indicate that p120-GAP is recruited
and associated to ZAP-70 after engagement of the TCR in
vivo. Early TCR signaling in agonist mode induces kinase
activity of lck and ZAP and that correlates with tyrosine
phosphorylation of the recruited p120-GAP. In contrast,
early TCR-mediated signaling in partial agonist mode fails
to induce kinase activity of lck and ZAP-70, and therefore
it is not able to induce phosphorylation of the recruited
p120-GAP.
 
Activation of ERK-1 and ERK-2 upon Early TCR-mediated
Signaling in Agonist and Partial Agonist Modes.
 
Activation of
p21
 
ras
 
 leads to recruitment and activation of Raf-1, which
Figure 5. Association of p120-GAP with ZAP-70 and lck upon dis-
tinct patterns of early TCR-mediated signaling. 3C6 T cells (107 cells/
lane) were stimulated with increasing concentrations of chimeric anti-
CD3-fos–anti-CD4-jun, anti-CD3-fos, or anti-CD4-jun antibodies for
10 min. T cells were then harvested and lysed in Triton-X 1%. Cell ly-
sates underwent immunoprecipitation with antibodies against p120-GAP
and subsequently immunoblotted for phosphotyrosine (a). Similar experi-
ments were performed and immunoblotted for ZAP-70 (b) or for lck (c).
Figure 6. Depletion of ZAP-70
upon sequential immunoprecipita-
tions with anti–ZAP-70 or with anti-
p120-GAP monoclonal antibody.
Two groups of 3C6 T cells (107 cells/
group) were stimulated with anti-
CD3-fos–anti-CD4-jun chimeric an-
tibodies (10 mg/ml), and subsequently
underwent immunoprecipitation with
antibodies against p120-GAP or with
antiserum against ZAP-70 followed by
two rounds of immunoprecipitation
with anti–ZAP-70 antiserum or anti-
p120-GAP antibodies, respectively,
and an additional immunoprecipitation with anti-p120-GAP or anti–ZAP-70 antibodies. The immunoprecipitates were immunoblotted with an antise-
rum against ZAP-70. Subsequently, the same membrane was stripped, reexposed to film to confirm complete stripping, and reblotted with a monoclonal
antibody against phosphotyrosine.1704 Signaling by Partial Agonist Ligands of the T Cell Receptor
then activates MEK-1 and MEK-2, which subsequently ac-
tivate ERK-1 and ERK-2 (24). Thus, we assessed the acti-
vation of these stages of the Ras-MAPK pathway by look-
ing at the levels of double phosphorylated ERK-1 and
ERK-2, as these are the active forms of ERK (24), and at
the kinase activity of ERK-1 and ERK-2 measured as serine
phosphorylation of exogenous Elk-1 as substrate. Immuno-
blotting with a monoclonal antibody against dual phosphor-
ylated ERK-1 (p44) and ERK-2 (p42) showed a significant
increase in these forms upon short stimulation with either
anti-CD3-fos or with anti-CD3-fos–anti-CD4-jun (Fig. 8
a). ERK-1 and ERK-2 activation remained high for at least
10 min in T cells stimulated by the agonist ligand as well as
in those stimulated by the partial agonist ligand. However,
upon CD3 and CD4 coengagement, ERK-1 and ERK-2
activation did not start to significantly decrease until after
30 min and was still detectable after 60 min of stimulation.
In contrast, ERKs activation decreased more rapidly after
partial agonist signaling, with significantly decreased levels
by 10 min after activation with bivalent CD3 engagement
and disappearance after 30 min. The possibility of differen-
tial activation of p42 or p44 at the initial time points is un-
likely given that the signal ratio for p44/p42 is similar for
both groups. As ERK activation decreases, the loss of p44
phosphorylation occurs faster than the loss of p42 phosphor-
ylation in both experimental groups.
These results were confirmed using in vitro kinase assays
for the ERKs (Fig. 8 b). Coengagement of CD3 and CD4
Figure 7. In vitro immune
complex kinase assay of p120-
GAP immunoprecipitates from
T cells stimulated in agonist or
partial agonist pattern of early
TCR-mediated signaling. p120-
GAP immunoprecipitates from
3C6 T cells (107 cells/lane) stim-
ulated with the appropriate chi-
meric antibodies were used for in
vitro kinase assay after addition
of exogenous 32P. Identity of the
bands were confirmed by parallel
immunoblotting of similar im-
munoprecipitates.
Figure 8. Activation of ERK-1 and ERK-2 after early TCR-mediated signaling in agonist or partial agonist pattern. (a) 3C6 T cells were stimulated
with the indicated heterofunctional antibodies (at a final concentration of 10 mg/ml) for increasing times, after which T cells were harvested and lysed.
Cell lysates (450,000 cell equivalents) were then immunoblotted with an antibody against dual phosphorylated ERKs. The bar diagram under a represents
the p44/p42 ratio of signal intensity of these bands for at least three different experiments. (b) Similarly, T cells (107 cells/group) were stimulated for in-
creasing times, after which T cells were harvested and lysed. Lysates underwent immunoprecipitation with phospho-specific anti-MAPK antibodies for
18 h. Immunoprecipitates were then incubated with exogenous Elk-1 substrate in kinase buffer containing ATP, and subsequently immunoblotted with
a phospho-specific anti–Elk-1 antibody. (c) Similar experiment to b, but using increasing concentrations of the different antibodies.1705 Chau et al.
for 2 min induced a significant increase in kinase activity of
ERKs as indicated by increasing serine phosphorylation of
exogenous Elk-1 (Fig. 8 b). Under these conditions, ERK
kinase activity remained high for up to 60 min. Bivalent
engagement of CD3 alone also induced a substantial in-
crease in phosphorylation at 2 min, which was equal to that
observed after full agonist TCR-mediated signaling. There-
fore, the initiation of ERK activation is similar after either
agonist or partial agonist engagement of the TCR. How-
ever, the kinetics of phosphorylation and phosphoprotein
decay of this pathway are distinctly different, with signifi-
cant loss of kinase activity after 10 min and almost com-
plete loss of activity after 30 min under conditions of partial
agonist signaling from the TCR. The increase in ERK
kinase activity seen after TCR-mediated signaling in ago-
nist mode or partial agonist mode were both dose depen-
dent (Fig. 8 c).
Discussion
Variant TCR ligands with partial agonist properties in-
duce a pattern of early TCR-mediated signaling that is dis-
tinct from the signals induced by agonist ligands (for re-
views see references 12, 20). Although agonist ligands
induce appearance of two forms of phospho–TCR-z (p21
and p23), phospho–CD3-e, and subsequent recruitment
and activation of ZAP-70, partial agonists of the TCR only
induce the p21 form of phospho–TCR-z and fail to acti-
vate recruited ZAP-70. This distinct signaling pattern cor-
relates with restricted T cell responses such as limited cy-
tokine production or induction of T cell anergy (7, 8).
Characterization of the steps linking the initial events after
receptor engagement with the downstream effector re-
sponses is important to understand T cell differentiation af-
ter TCR ligation. The results presented in this paper dem-
onstrate that stimulation of T cells in a partial agonist mode
after bivalent engagement of CD3 causes recruitment and
association of p120-GAP with ZAP-70, and activation of
the Ras-MAPK pathway. However, in contrast to full ago-
nist pattern of TCR-mediated signaling, partial agonist
TCR-mediated signaling activates ERK-1 and ERK-2
only transiently, either because of lack of sustained stimula-
tion and normal decay or because of faster inactivation of
these serine/threonine kinases.
We have shown that p120-GAP can associate with
ZAP-70 in vivo after early TCR-mediated signaling in ag-
onist mode and in partial agonist mode. However, only full
agonist type of signaling induced phosphorylation of p120-
GAP. This is expected since only agonist ligands induce ac-
tivation of lck and of ZAP-70 (13, 14), and lck can act as a
kinase on ZAP-70 (36) and on p120-GAP (50). On the
other hand, the partial agonist pattern of TCR-mediated
signaling failed to activate the kinase activity of lck and did
not induce association of p120-GAP to this src-kinase. This
could explain the lack of tyrosine phosphorylation of ZAP-70
and of p120-GAP (34). The dissociated recruitment and
activation of signaling molecules after partial agonist signal-
ing from the TCR may have profound functional conse-
quences. This is well established for ZAP-70, for which re-
cruitment and activation are two separate, discrete events,
and for which tyrosine phosphorylation correlates with ki-
nase activity (14, 36, 52, 53). The biological implications of
tyrosine phosphorylation of p120-GAP are still unknown.
What is the molecular basis for the association between
p120-GAP and these kinases? In the agonist type of signal-
ing, both lck and ZAP-70 are tyrosine phosphorylated and
active. Given that p120-GAP has two SH2 domains (48),
the association of p120-GAP to these molecules can be ex-
plained on the basis of SH2-mediated interactions with
phospho-tyrosine-based motifs, as previously reported (54).
However, the molecular mechanism by which the ZAP-
70–p120-GAP association occurs after early TCR signaling
in partial agonist mode is not clear because, in these condi-
tions, ZAP-70 is not phosphorylated, excluding SH2-
mediated interactions between these two molecules. Two
possible mechanisms can be proposed. One is that p120-
GAP associates with ZAP-70 through an interaction in-
volving the SH3 domain of p120-GAP and a proline-rich
region in ZAP-70. Close examination of the ZAP-70 se-
quence shows that it contains a PTLPAHP stretch between
residues 267 and 274, downstream of the SH2(C) domain
(52). This sequence conforms to the consensus sequence
for SH3 domain binding (55). This claim is further sup-
ported by the similarity between this sequence and the pro-
line-rich sequence in G3BP (PQRPQR) that likely medi-
ates the high affinity binding between this protein and the
SH3 domain of p120-GAP (56). The PTLPAHP sequence
only contains relatively minor substitutions between the
proline residues. This mechanism would be similar to that
reported for MAPK recruitment to the TCR via SH3 in-
teractions with lck (57). Alternatively, the association be-
tween ZAP-70 and p120-GAP may occur through an in-
termediate molecule to which both bind through their
SH2 domains. One potential candidate could be a TCR
subunit such as TCR-z or a CD3 chain because these are
phosphorylated in tyrosines after partial agonist type of sig-
naling from the TCR, and we know that this is sufficient
for ZAP-70 recruitment (14). However, we have failed to
detect the presence of TCR subunits by direct blotting of
p120-GAP immunoprecipitates as well as by phosphoty-
rosine blotting of these samples. Another candidate could
be p62-Sam68 (58, 59), although we do not have any indi-
cation of a tyrosine phosphorylated protein of this range in
p120-GAP immunoprecipitates.
How does activation of ERK-1 and ERK-2 occur after
TCR-mediated signaling in partial agonist mode? Our re-
sults indicate that coengagement of CD4 with CD3 is not
necessary for activation of the Ras-MAPK pathway, but it
is required for optimal and sustained activation of this path-
way (60). Coengagement of CD3 and CD4 may be espe-
cially important when the affinity of the TCR for its ligand
is low, such as in the case of weak agonist ligands (61) or
partial agonists and antagonists of the TCR (62, 63). Under
these conditions, CD4 coengagement may increase the sta-
bility of TCR–peptide–MHC molecule complex engage-
ment and provide sustained TCR-induced signaling (64).1706 Signaling by Partial Agonist Ligands of the T Cell Receptor
Our finding of transient activation of MAPKs in the ab-
sence of CD3–CD4 coengagement is therefore compatible
with our previous model in which the efficiency of TCR–
CD4 coengagement determines the quality of TCR-medi-
ated signaling and partial agonism (33, 34). The transient
kinetics of MAPK activation after partial agonist stimula-
tion supports a CD4-dependent kinetic basis for differential
TCR-mediated signaling by partial agonist ligands. TCR
antagonism may represent conditions of a much lower
range of TCR affinity that correlate with very transient or
undetectable ERK activation (65).
It is important to note that bivalent engagement of CD3
may be a critical feature in the induction of partial agonist
signaling in our experimental model, in line with recent
claims that oligomerization of the TCR may be needed for
initiation of signaling (66). The specific CD3 dimerization
induced by our chimeric antibodies, in contrast to anti-
body-induced cross-linking (59), could explain the differ-
ences between our data showing lck-independent activa-
tion of ERKs and previous reports claiming that ERK
activation is primarily lck dependent (67, 68). Some
ligands, including the chimeric molecules used here, may
induce receptor dimerization with the proper architecture
to cause PKC-dependent activation of Raf-1 and ERK
(69–72) in the absence of lck activation (68, 73). In vivo
data would support this model. For example, although lck-
deficient mice have a drastic reduction in the total number
of double positive thymocytes, they still have a significant
proportion of these cells (74). This would support a lck-
independent pathway for MAPK activation given that dif-
ferentiation into CD41CD81 thymocytes is critically de-
pendent on activation of the MAPK pathway (75–77).
Based on the above mentioned considerations, we pro-
pose that partial agonist-induced differential phosphoryla-
tion of TCR subunits causes activation of Ras. This could
be the result of activation of a kinase other than lck (possi-
bly fyn; reference 78), which would concomitantly recruit
ZAP-70 and activate some other signaling molecules like
p95vav that shares homology with some guanine nucle-
otide releasing factors involved in Ras activation (79, 80).
Ras activation would then recruit different effector mole-
cules to the cell membrane, including Raf (81) and p120-
GAP. Activation of Ras and Raf-1 would then result in ac-
tivation of ERK-1 and ERK-2. In addition, the presence
of p120-GAP in proximity to engaged and differentially
phosphorylated TCR would favor the association of p120-
GAP with recruited, TCR-associated ZAP-70. Although
we have not ruled out an indirect association between
these two molecules, we suggest that this would occur
through proline-rich–SH3 domain interactions. An effector
function of p120-GAP other than acting as GTPase is still
unknown (45).
The demonstration of the flexibility of TCR-mediated
recognition and consequent T cell responses raises an inter-
esting question related to downstream signaling by variant
TCR ligands. That is, does differential early TCR-medi-
ated signaling result in a similar decrease in activation of all
downstream pathways? Or conversely, does this differential
signaling correlate with preserved activation of some path-
ways but not others? Our data would support a model of
dissociated activation of some signaling pathways, but not
others. This could reflect different requirements of sus-
tained signaling for each signaling pathway emanating from
the TCR. Such a model is also supported by two recent re-
ports indicating that partial agonists of the TCR can induce
low and transient calcium signals that do not correlate with
detectable generation of inositol trisphosphates (17, 18). The
different thresholds of activation for downstream pathways
would then correlate with different patterns of effector T
cell responses as recently reported (82). The ability to disso-
ciate signaling pathways may have fundamental biological
implications in the design of immunomodulatory strategies
that target specific signaling pathways whose activation re-
sults in split T cell responses. In this sense, selective activation
of the Ras-MAPK pathway may reproduce some of the ef-
fects seen after TCR engagement with partial agonist ligands.
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